

Figure S1 Screening for targeted genes. A DEG analysis between low and high immune scores. **B** DEG analysis between low and high stromal scores. **C** WGCNA analysis for identifying gene modules. **D** Correlation between immune, stromal and ESTIMATE scores and gene modules. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001. **E** Venn plot displays the number of immune-related genes between DEG analysis and WGCNA. **F** Venn plot displays the number of stromal-related genes between DEG analysis and WGCNA. **G** The immune-related genes were further inputted into LASSO analysis. **H** The intersection stromal-related genes were further inputted into LASSO analysis. The Y-axis shows LASSO coefficients and the X-axis is  $-\log$  (lambda). And the output genes were in the right rectangle boxes.

**Abbreviations:** DEG, differentially expressed gene); WGCNA, weighted correlation network analysis ; LASSO, Least absolute shrinkage and selection operator

## Α

В

С

Factor	Univariate Cox analysis			Multivariate Cox analysis		
Factor	HR(95%	6 CI)	p value	HR(959	% CI)	p value
riskscore	2.545 (1.584-	-4.090)	< 0.001	2.080 (1.313	3-3.295)	0.002
Μ	4.052 (2.593-	-6.333)	< 0.002	1.946 (0.881	1-4.299)	0.1
Ν	1.961 (1.560-2.464)		< 0.003	1.340 (0.899	9-2.000)	0.151
Т	2.411 (1.648-3.527)		< 0.004	1.789 (1.120-2.859) 0.0		0.015
Stage	2.046 (1.628-	-2.571)	< 0.005	1.266 (0.711	1-2.252)	0.422
Age	1.028 (1.010-	-1.046)	0.002	1.036 (1.018	8-1.054)	< 0.001
Points		0 10	20 30	40 50 60	0 70 80	) 90 100
Riskscore		0 0.2 0.4	0.6 0.8 1	1.2 1.4 1.6 1.	8 2 2.2 2.4	4 2.6 2.8 3
Gender		male				
Age		30 35 4	40 45 50	55 60 65	70 75 8	30 85 90
Т		1	2	3	4	
Ν			7	5		
М		0 0	.5 2			
Stage		2	4			
Total Points		0 50	) 100	150 200	250	300 350
Linear Predicto	r	-2.5	-2 -1.5 -1 -	0.5 0 0.5 1	1.5 2 2.5	3 3.5 4
1-year Surviva	l Probability			0 0 0 8	07.060504030	, , , , , , , , , , , , , , , , , , , ,
3-year Surviva	l Probability		F	0.9 0.8		5.2 0.1
5-year Survival Probability						
5-year Surviva						
5–year Surviva	,		0.9 (	0.8 0.7 0.6 0.5 0.4 0.3	3 0.2 0.1	
5–year Surviva	ŗ		0.9 (	0.8 0.7 0.6 0.5 0.4 0.3	3 0.2 0.1	
5-year Surviva	I	Observed OS (%) 0.0 0.2 0.4 0.6 0.8 1.0	0.9	0.8 0.7 0.6 0.5 0.4 0.3 0.7 0.6 0.5 0.4 0.3 0.7 0.6 0.5 0.4 0.3 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	3 0.2 0.1	

Figure S2 **Prognostic analysis of BST2 in CRC. A** Univariate and multivariate Cox regression analysis of riskscore, TNM stage, age and gender. **B** Prognostic nomograms based on risk score, TNM stage, age and gender. **C** Calibration analysis of the nomogram for predicting 1-year, 3-year and 5-year overall survival, respectively.











Figure S3 **The correlation analysis between BST2 and various immune factors. A** The heatmap showed the correlation between BST2 and immune cells in various cancers. **B** The heatmap showed the correlation between BST2 and immune stimulators in various cancers. **C** The heatmap showed the correlation between BST2 and immune inhibitors in various cancers. **D** The heatmap showed the correlation between BST2 and MHC molecules in various cancers. The plot above were downloaded from http://cis.hku.hk/TISIDB/









С











## Figure S4 Distribution of BST2 in different types of immune cells analyzed in three single cell RNA-seq datasets. A GSE146771; B GSE146771; C GSE139555; Different colors represent different kinds of immune cells.



Figure S5 **A** Difference analysis of the distribution of BST2 expression between non-responder and responder prior therapy. **B** ROC analysis of BST2 expression prior therapy in predicting the ICB response. **C** Difference analysis of the distribution of BST2 expression between non-responder and responder post therapy. **D** ROC analysis of BST2 expression post therapy in predicting the ICB response. **E-I** qRT-PCR (E-F), Western blot analysis (G) were used to certificate the knockdown of BST2 in RKO, and the downregulation of PD-L1 in RKO. Flow cytometry analysis to further certificate the downregulation of PD-L1 in RKO (H-I). **J** Western blot analysis was used to certificate the overexpression of BST2 in RKO. **L** BST2-knockdown RKO cells were applied to cell cycle analysis assays. **M** The percentage of RKO cells in G0/G1, S and G2/M phases. \*P < 0.05; \*\*P < 0.01; ns, not significant. **N** qRT-PCR analysis was applied to demonstrate the M1 polarization when TAMs cocultured with BST2-knockdown RKO cells.